Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 10/20 | 0.49 |
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | OGA | O60502 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12199712 | 0.86 | OGA (0.53) | GRM5MAPTTP53NPC1RAB9A | |
| SCHEMBL12199709 | 0.82 | POLB (0.40) | GRM5NPC1RAB9AOGASMN1; SMN2 | |
| SCHEMBL30717355 | 0.81 | NPC1 (0.43) | GRM5MAPTTP53NPC1RAB9A | |
| SCHEMBL12199715 | 0.80 | GRAMD1A (0.46) | MAPTNPC1RAB9AOGA | |
| SCHEMBL12199714 | 0.76 | HDAC3 (0.49) | GRM5MAPTOGASMN1; SMN2 | |
| SCHEMBL30717490 | 0.73 | CNR1 (0.40) | GRM5MAPTTP53NPC1RAB9A | |
| SCHEMBL12199711 | 0.72 | TAS1R3 (0.48) | MAPTNPC1RAB9AOGA | |
| SCHEMBL12199724 | 0.72 | KMT2A (0.43) | MAPTTP53NPC1RAB9AOGA | |
| SCHEMBL12199713 | 0.70 | SLC27A1 (0.47) | GRM5TP53NPC1RAB9AOGA | |
| SCHEMBL30717349 | 0.70 | GRM5 (0.52) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110245267-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING PLOUGH CORPORATION (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110245267-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING PLOUGH CORPORATION (US) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245267-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GID4, IL5 | GRM5 33/4885MAPT 908/4885HSD11B1 2808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.